The FDA has asked drugmakers to pull all prescription and over-the-counter products based on ranitidine off the market immediately, after a review failed to alleviate concerns about a cancer risk.

NDMA is a probable human carcinogen, a substance that could cause cancer, the FDA said in April 2020, when the agency asked ...

This lawsuit concerns GSK’s fraud on the federal and state governments and the money spent on ranitidine products by governments because of that fraud. Whether ranitidine increases the risk of cancer ...

In a statement Wednesday, Valisure said the results from its research on acne treatments were most similar to its ...

GSK and Sanofi have both said that NDMA levels in ranitidine products is lower than would be encountered naturally in the diet. In its latest statement, GSK notes that a multidistrict litigation ...

US retailer CVS has become the latest to suspend the sale of a heartburn drug being investigated for links to cancer. It follows concern in several countries over the presence of impurities in ...

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...

Only two commercial ranitidine products were assessed for NDMA content via analysis. Powdered samples (100 to 500 mg) were introduced to 10 mL headspace vials for headspace analysis without ...

Corrects headline to say 'settlements' instead of 'settlement' British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to lawsuits ...

GSK Plc said it will pay as much as $2.2 billion to resolve about 80,000 US court cases related to allegations that its old reflux medication Zantac was contaminated with a suspected carcinogen.

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug. GSK suffered ...